Stock Track | Humacyte Reports Wider Q3 Loss, Pre-Market Stock Surges

Stock Track

Nov 08, 2024

Humacyte, Inc. (HUMA) reported financial results for the third quarter ended September 30, 2024. The biotechnology company's stock surged 5.51% in pre-market trading following the earnings release despite posting a wider net loss compared to analyst estimates.

Humacyte reported an operating loss of $30.23 million for Q3 2024, slightly higher than the consensus estimate of $29.7 million. The net loss for the quarter came in at $39.2 million or $0.33 per share, compared to analysts' expectations of a $30 million loss.

The company did not provide additional commentary in the earnings release to explain the stock's pre-market surge. Investors may be reacting positively to other factors beyond the headline financial metrics. More details on Humacyte's outlook and future milestones could shed light on the stock movement when the company holds its earnings call later today.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1172869796"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1172869796\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1172869796?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172869796","market":"us","top_or_hot":-1,"title":"Stock Track | Humacyte Reports Wider Q3 Loss, Pre-Market Stock Surges","media":"Stock Track","content":"<p>Humacyte, Inc. (HUMA) reported financial results for the third quarter ended September 30, 2024. The biotechnology company's stock surged 5.51% in pre-market trading following the earnings release despite posting a wider net loss compared to analyst estimates.</p>\n\n<p>Humacyte reported an operating loss of $30.23 million for Q3 2024, slightly higher than the consensus estimate of $29.7 million. The net loss for the quarter came in at $39.2 million or $0.33 per share, compared to analysts' expectations of a $30 million loss.</p>\n\n<p>The company did not provide additional commentary in the earnings release to explain the stock's pre-market surge. Investors may be reacting positively to other factors beyond the headline financial metrics. More details on Humacyte's outlook and future milestones could shed light on the stock movement when the company holds its earnings call later today.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Humacyte Reports Wider Q3 Loss, Pre-Market Stock Surges</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Humacyte Reports Wider Q3 Loss, Pre-Market Stock Surges\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-08 21:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Humacyte, Inc. (HUMA) reported financial results for the third quarter ended September 30, 2024. The biotechnology company's stock surged 5.51% in pre-market trading following the earnings release despite posting a wider net loss compared to analyst estimates.</p>\n\n<p>Humacyte reported an operating loss of $30.23 million for Q3 2024, slightly higher than the consensus estimate of $29.7 million. The net loss for the quarter came in at $39.2 million or $0.33 per share, compared to analysts' expectations of a $30 million loss.</p>\n\n<p>The company did not provide additional commentary in the earnings release to explain the stock's pre-market surge. Investors may be reacting positively to other factors beyond the headline financial metrics. More details on Humacyte's outlook and future milestones could shed light on the stock movement when the company holds its earnings call later today.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HUMA","symbol_name":"Humacyte, Inc.","start_time":0,"source_url":"","article_id":"1172869796","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172869796","pubTimestamp":1731071187,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Humacyte, Inc.  reported financial results for the third quarter ended September 30, 2024. The biotechnology company's stock surged 5.51% in pre-market trading following the earnings release despite posting a wider net loss compared to analyst estimates.Humacyte reported an operating loss of $30.23 million for Q3 2024, slightly higher than the consensus estimate of $29.7 million. The net loss for the quarter came in at $39.2 million or $0.33 per share, compared to analysts' expectations of a $30","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HUMA":"Humacyte, Inc."},"translate_title":"股票追踪Humacyte报告第三季度亏损扩大，盘前股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HUMA":1},"content_text":"Humacyte, Inc. (HUMA) reported financial results for the third quarter ended September 30, 2024. The biotechnology company's stock surged 5.51% in pre-market trading following the earnings release despite posting a wider net loss compared to analyst estimates.\nHumacyte reported an operating loss of $30.23 million for Q3 2024, slightly higher than the consensus estimate of $29.7 million. The net loss for the quarter came in at $39.2 million or $0.33 per share, compared to analysts' expectations of a $30 million loss.\nThe company did not provide additional commentary in the earnings release to explain the stock's pre-market surge. Investors may be reacting positively to other factors beyond the headline financial metrics. More details on Humacyte's outlook and future milestones could shed light on the stock movement when the company holds its earnings call later today.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}